Revance Therapeutics Inc. closed a $45 million debt financing and will use the proceeds to advance lead candidate RT001 botulinum toxin type A topical gel, currently in Phase II trials for lateral canthal lines (crow's feet wrinkles) and hyperhidrosis (excessive sweating), and a preclinical injectable botulinum toxin type A product RT002.